Ripping Off Rings – Another confused decision by the Israel Court

March 29, 2011

H Stern's ring

H. Stern, a Brazilian jewelry manufacturer with many retail outlets in Israel and an international presence sells a finger ring. The ring is a flat gold band with a diamond encrusted oblong section and the rest of the band being polished to a mirror finish. The band is also decorated with a pentagram or Seal of Solomon on the shiny part on each side of the diamond oblong. 5 pointed stars are also engraved on the inside of the band. The ring is known as the Juliana model.

Aryeh Pozylov, through various companies including Orneal LTD, Nitfaz (a pun on nitfas, i.e. snapped up) and Pozylov Diamonds marketed a somewhat similar but substantially cheaper ring which has Star of David (Magen David, or Hexagram) decorations.  The pentagram is a registered trademark for H. Stern, chosen since Stern means a star.

Stern sued Pozylov invoking a number of causes of action including:

  •  trademark infringement
  • well-known mark infringement
  • passing off
  • copyright infringement
  • unjust enrichment
  • dilution
  •  stealing reputation and confusing the consumer

The Ruling

As to trademark infringement, Judge Pilpel ruled that the pentagram and the hexagram are arguably confusingly similar to look at, but for jewelry, the purchaser is particularly careful. She went on to rule that this is not all that relevant since according to Judge Gronish in the Taam Teva decision, when applying the so-called triple test, the appearance of the mark is of less importance than the sound of the mark when considering the “sight and sound test”, and pentagram sounds different from Magen David, therefore there is no likelihood of confusion(!)

Although the products under consideration are rings in both cases, since H. Stern does not sell via third parties, there is no real likelihood of confusion. Finally, Judge Drora Pilpel applied the fourth part of the triple test, the so-called ‘clear thinking test’, and decided that even though the sound of the mark was different (the ringing of the ring?), since the conceptual idea between Stern’s mark was to imply the maker, using a star (Stern being German for Star) as a maker’s mark, whereas the defendant’s Star of David implies made in Israel, there was no likelihood of confusion.

As to whether the trademark of the pentagram was well-known, Judge Pilpel related to the issue at some length, which is surprising, since she has already decided that there is no trademark infringement. Nevertheless, she decided that it wasn’t, despite the complainants remonstrations to the contrary.

The judge acknowledged that the plaintiff had a reputation for the Juliana design and that it was associated with them to some extent, but did not think that the public would be confused as to the source of the goods since H. Stern only sells rings in their own shops.

The defendant argued that copyright could not be applied since the ring could and should have been protected as a design. The judge dismissed this in a strange line of reasoning that I had difficulty following. Essentially, she argued that this was true of mass-produced machine manufactured objects but not of hand-made goods, and although clothing could and should be protected as designs and were not protected by copyright, jewelry could be.  She went on to rule that the combination of the shiny band, diamond encrusted oblong and stars were protected by copyright(!)

 Having recognized copyright in the combination of the three design elements, the judge went on to rule that the fact that one ring had hexagrams and the other pentagrams were not significant enough to alter the fact that the defendants ring was a blatant copy.

Since she had found copyright infringement, the judge considered the question of unjust enrichment irrelevant.

As to dilution and stealing reputation, the court threw this out for lack of proof of damage to H. Stern.

In conclusion, the judge found statutory damages of NIS 20,000 under the Copyright Ordinance of 1911 that was in force when the case was filed, and in the alternative, found that the plaintiff would be entitled to profits made by the defendant from the infringing rings. The judge also awarded NIS 40,000 costs.

Finally, the judge ordered the unsold stock of rings and the molds to be destroyed and for the defendant to cease advertising or selling these rings.

T.A.  1253/05 H. Stern Brazil and H. Stern Israel vs. Ornil and Pozylov, 13 March 2011 by Judge Drora Pilpel

Comments

Had the plaintiff filed a design registration they could have got an injunction and enforced their rights more simply and quickly.

The honorable judge apparently has little idea of how to apply the so-called triple test. The test of the sound and appearance of a trademark has relevance for a word mark, where goods are chosen by sound. The fact that Pentagram and Magen David sound different is totally irrelevant. The only question is whether the pentagram is recognizable as a trademark when applied to the ring, and whether the hexagram is confusingly similar. If the mark is seen as part of the design or the two marks are considered as distinctive in context, then there is no trademark infringement. If, however, the marks are confusingly similar, then there is trademark infringement. The fact that the word hexagram has two identical syllables as pentagram is totally irrelevant.

I suppose it would be churlish to point out that neither of Stern’s registered trademarks is actually for a single pentagram.

Stern’s Israel trademark registration number 170325 is for a five pointed star, not for a pentagram at all. The stars on the inside of the band are a registered trademark, the pentagram on the outside with a diamond in it, is not.

Does Stern use the pentagram on all their jewelry? Is the symbol widely used by them on the reverse of pendants, bracelets and rings? If so, it may fairly be considered as an unregistered trademark. Otherwise, it would probably be considered a design feature by the purchaser or the receiver of the gift. Only if it can fairly be considered as being a trademark at all, is the issue of whether the hexagram mark is confusingly similar.

In this regard, the hallmark for Britannia grade silver (95.84%) is a leopard head or a lion head erased, or, since 1999, with the number 958. The UK sterling silver hallmark is a lion passant. Sterling silver in Israel is indicated by the number 925, and Russian Silver by the number 880. These numbers and hallmarks are indicative of the relevant degree of similarity for trademarks in this field. I am not a judge. The right honorable Ms Pilpel is. She should, however, apply her judgment to relevant issues.

As to the issue of Stern only selling via their retail outlets, the point has some relevance, but would the receiver of a gift know where it was bought? Is jewelry never sold second-hand? The clear thinking test was anything but.

The judge really meant to say was that the purchaser would consider the Magen David a design element, not an indication of the source fo the goods. Therefore there was no trademark infringement.

No design was registered, and therefore there was no infringement.

As to copyright, in Israel although the design law which dates back to the British Mandate is sorely in need of revising, there are no unregistered design rights. Any mass-produced article is protectable as a registered design and is protectable for up to 15 years. By allowing copyright protection for such goods, presumably for life of the creator + 50 years, why would anyone register designs?

Since H Stern’s ring was designed for mass production, there is no copyright. That said, having wrongly established copyright the judge was correct in seeing it infringed by the defendant’s ring.

I am also unimpressed with the judge seeing copyright in the combination of three design elements, since H. Stern had argued that the pentagram was a trademark and not a design element. This should have estoppeled them from claiming it was part of the design, and with just the polished band and diamond oblong bit, Stern’s ring would not be sufficiently distinctive to attain copyright protection even if copyright applied, which in this case, under Israeli law, should not.  

It is a shame that the judge found it superfluous to rule on unjust enrichment because one assumes that the finding of copyright infringement would not stand up in court. Following the high court ruling in the A.Sh.I.R. case which is good legal precedent (even if arguably a poor decision), there are grounds to apply the Law of Unjust Enrichment where designs were not registered, if there is evidence of bad faith. In this case, I am not sure that there are grounds,  since I see this as an unregistered design in the public domain, nevertheless, think the judge could have been more thorough.


Alexandria – Health Science; not health related nor scientific, but so what?

March 27, 2011

Alexandria Real Estate Equities Inc. filed Israel Trademark Applications Numbers 203221 to 203225 for the word mark Alexandria – Health Science in classes 35, 36, 27, 39 and 42 for a variety of services relating to real estate. On examination, the marks were refused unless the applicant disclaimed the phrase “health science”. 

Usually disclaimers are required where words are generic or descriptive to prevent an applicant from preventing third parties from using the term.   In this case, the trademark examiner felt that the term was misleading since the services provided had nothing to do with health or science.

Arguments that the term had been trademarked abroad were (correctly) dismissed as being hardly relevant.

The applicant claimed that there were no grounds for refusing the mark for confusion but agreed to disclaim the words science and health individually. The examiner wasn’t satisfied and the applicant appealed to the Commissioner of Patents and Trademarks.

Ms Yaara Shoshani Caspi upheld the right of the patent and trademark office to defend the populace against confusing brands under Section 6(11) and 18 of the Law, but felt that marketing storage rental, architectural design services, real estate development services  and the like as health science was unlikely to create a confusion with the regular customers or with the medical profession as to the scientific or health benefits of such services. Furthermore, following Commissioner of trademarks Circular MN 84 from 6 September 2010, there is no need to disclaim generic terms, so she allowed the mark to continue to allowance with neither word science nor health disclaimed.  

COMMENT

I am pleased that the patent office has decided not to widely refuse marks as being confusing to the public. Israel’s largest company, Teva, meaning natural, makes pharmaceuticals. The term Christian Science  http://en.wikipedia.org/wiki/Christian_Science is not science as commonly used. Were this refusal to have been upheld, there would be room for a lot of mischief.

 I am not sure why the Realty company has called itself health science, but submit that it hardly matters.


Israel Patent Attorney Card Not Recognized by Court Security Personnel

March 24, 2011

One of my fellow Israel patent attorneys asked me recently what use is the nice plastic identity card that the Ministry of Justice has issued to patent attorneys?

I explained to him that it enabled the lucky possessors to enter Israeli court-houses like attorneys-at-law and their article clerks can – i.e. without emptying pockets and going through an electronic security gate.

Well today I tested this theory in the Tel Aviv Magistrate’s Court. To my chagrin neither security guard knew what the card was and when I explained one muttered into his communication device and was told that the card wasn’t recognized. I was sent back to the line.

I call on our representative body, the IAPA, its illustrious Chairman, Ms Michal Hackmey, and the other honorary officers to deal with this problem forthwith.  It is embarrassing to hold up proceedings or to miss a hearing due to these unneccessary delays.

In the meantime, a prize for the best (publishable)  suggestion for what Israel Patent Attorney cards are useful for.


Frank Neuhauser Passes Away

March 23, 2011

Frank Neuhauser, a patent attorney of 71 years, passed away, aged 97, on 22 March 2011.

Despite an illustrious career that included working as in-house patent attorney at General Electric, Neuhauser is best known for having won the first ever US National Spelling Bee back in 1925, aged 11, by spelling the word gladiolus.

I find this fascinating. A tremendous but rather pointless achievement.

Coincidentally, my greatest academic achievement was also aged eleven, when I scored 100% in the Inner London Education Authority standardized test – the 11+, consisting of reasoning, maths and English comprehension. 

My colleague, Yaakov Schatz, a highly competent patent attorney, was apparently a late developer. He was a teenager when he won the Israel National Independence Day Bible Quiz, which the popular satirist Ephraim Kishon famously compared to memorising and being tested on the numbers and addresses in the phone book.

Eran Liss, an upcoming Israeli IP litigator, was the World Under 16 chess champion. 

Not all patent attorneys peak in the early years though. Apparently, an Australian patent attorney won the Master Chef competition on television last year.   

For more on Neuhauser, see the obituary in the New York Times: http://www.nytimes.com/2011/03/23/us/23neuhauser.html


Given Imaging Obtains Injunction Against Intromedic

March 22, 2011

Given Imaging Ltd, an Israeli company who developed an ingestible camera (PillCam) for imaging the digestive tract have announced that a regional court in Düsseldorf, Germany have ruled in its favor in a patent infringement lawsuit they brought against IntroMedic, a South Korean company, and have found that Intromedic’s MiroCam capsule endoscopy system infringes two patents relating to capsule endoscopy.

The Israeli firm developed an endoscopy system that uses miniature video cameras in a capsule to provide physicians with clear images of the small intestine. This is apparently more pleasant and less evasive than fiber endoscopy. The capsule is excreted in due course.

The ruling allows Given Imaging to prevent IntroMedic’s German distributor, Medwork, from selling the current model of the MiroCam capsule and MiroView software in Germany. However Medwork has appealed the ruling. However, separate proceedings attempting to invalidate Given Imaging’s patents were initiated by IntroMedic and Medwork and are pending before the German Federal Patent Court.


Maariv Newspaper Obtains Injunction Against Quorum Formers

March 18, 2011

Maariv Newspaper is a daily Israeli paper whose first edition comes out in the evening, hence the name which comes from means evening. Maariv is also a name given to the Evening Prayer service.

In various public areas such as bus stations and shopping centers, it is common to hear calls of Maariv, and it has hitherto been unclear as to whether the caller was hawking papers, or calling the faithful to prayer – specifically trying to get a quorum together. Claiming dilution of their trademarked name, Maariv newspapers filed suit for an injunction against use of the word Maariv as a means for gathering a quorum for the evening service. Jerusalem District Judge Asa Schock has ruled that henceforth Ashkenazic Jews of East European ethnicity will have to use the sefardaic variant term Arvit.

An appeal to the Court on High has been filed.

The case: Maariv Newspaper VS. Jewish Tradition

This development has raised a lot of controversy with the usual unholy trinity of politicians, Rabbis and journalists vying for sound bites.

A spokesman for Rav Ovadia Yosef commented that Maran has ruled that as there was historically a Sefardaic majority in the Holyland, all Ashkenazic jews were absorbed by the majority and should adopt Sefardic custom. Since Maariv is not the correct name of the Evening Service, there is no likelihood of confusion.

MK Gafni felt that as the Maariv paper included pictures of women, it was suitable for sale in polyethylene wrappings only on top shelves in exclusively secular neighborhoods only and by restricting it’s distribution in such a manner, the problem would be solved.

Retired Supreme Court Judge Dalia Dorner, now serving the Journalism Association, has stated that after Aggranat’s Kol Ha-Am decision, it was clear that allowing other parties to refer to Maariv when not implying the newspaper would be an incursion of journalistic freedom.

MK Zippi Livni has requested a review of Maariv’s reporting regarding Kadima before deciding whether Knesset legislation is in order.

The Baa Baa Blacksheep ruled that referring to an Ashkenazic Service as Arvit was misleading as worshippers would be mislead into believing that the service would include various psalms and other extra readings.

Due to his full time occupation supervising meat and citrus fruit the Hatam Sofer was unavailable to comment.

The Rentgen claimed to have foreseen these developments.

The BBC’s coverage of the story, titled “Communal Prayers at the Western Wall Provocation by Settlers” argued that any Jewish prayer gathering between the Jordan and the Mediteranean was illegal occupation.

In a terse statement, US Foreign Secretary Hilary Clinton affirmed that this development should not be allowed to adversely affect the Peace Process.

MK Ahmad Tibi declined to comment, stating that that the correct term for prayer was an exclusively Jewish matter.


Israel Tech transfers Announce Deal With Google

March 17, 2011

The tech-transfer organizations of the Hebrew University, Tel Aviv University and the Haifa Technion have closed a deal with Google, under which the universities will engage in research into online auctions, gaming and the like.

See http://www.businesswire.com/news/home/20110316005678/en/Hebrew-University-Tel-Aviv-University-Technion-Sign for further details.

COMMENT

Despite doing IP work for all the organizations concerned, I view the above development with distaste.

I am in favour of academic research that results in patentable inventions that are filed by tech transfer organizations and then licensed to commercial parties, providing that the inventors can and do publish their research. In this regard, we note that patent applications once published, are a form of publication in all respects.

I also have no problem with universities undertaking applied research of commercial importance. Nor do I have a problem with universities accepting endowments from commercial entities, such as google.

What I am not so keen on is what appears to be intellectual prostitution wherein the organisations that should be creating knowledge for furthering society are becoming R&D centers for commercial organizations. My Ph.D. research at the Hebrew University was funded by and connected to an R&D project with commercial aspirations. Nevertheless, it was undertaken at a university, not at the McDonalds University of Fast Food.

I don’t like to see Israel universities held by their googlies. I do not want my income tax contributions to be used as a sort of Israel govt. R&D loan to Google. However, I acknowledge that I have not read the agreements, only the press release. Maybe I am exaggerating.


Asa Kling Selected as Israel Commissioner of Patents & Trademarks

March 13, 2011

Asa Kling

According to the Mekor Rishon newspaper, Adv. Asa Kling has been selected as the next Israel Commissioner of Patents and Trademarks. Kling has an LL.B, from Tel Aviv University from 1997; and a B.Sc. in Aerospace Engineering from the Technion, Israel Institute of Technology. Kling is currently a partner of Gilat Bareket, the legal side of the Reinhold Cohn Group, where, according to their website, he handles various aspects of intellectual property law, antitrust law, commercial law, company law and international transactions.

He has litigation experience relating to patents, copyright and trademarks and cross-border intellectual property enforcement. Assuming the Minister of Justice Yaakov Neeman confirms the appointment, we wish Adv. Kling success in his new position.

COMMENT

We note with approval that Adv. Kling has both legal and engineering qualifications, with IP experience as both a patent attorney and an attorney-at-law. Interestingly, Kling’s Patent Attorney license, No. 280, is only from 2006. It is odd to find myself licensed as a patent attorney for longer than the incoming Commissioner.

Then again, Kling does have the three years post licensing experience to train budding patent attorneys, and there is no legal requirement for a commissioner to be a patent attorney at all. Kling does, however, have the 10 years post licensing experience required for a district court judge, which is the equivalent position.

Some may consider it not ideal for an Israel Commissioner of Patents and Trademarks to have been a partner in the largest IP Group. If Kling disqualifies himself from handling cases where Reinhold Cohn is a party, he may find himself unable to rule on a large number of cases. Since the Deputy Commissioner and other adjudicators are subservient to him, there is a problem even if he disqualifies himself. There is also a danger of Kling taking a strong line against RCIP clients so as to appear balanced.

In my opinion, because of the possibility of appeal to the courts, the problem is not overly serious in practice. Since decisions are published, third parties such as me can freely criticize what we consider to be misinterpretations and poor decisions. Indeed, way back when then Acting Commissioner Yisrael Axelrod found in favor of RCIP’s clients when interpreting the law regarding pharmaceutical patent term extensions in a ruling where only RCIP’s clients were involved, the Knesset amended the Law to make his interpretation untenable.

We hope that Kling, if his appointment is affirmed, will either not patronize any IP events organized by firms in the private sector, will patronize them all or will publish guidelines for participation of patent office staff. Dr Noam had a strong policy of not attending events organized by IP firms and also prevented heads of departments from actively participating. However, on occasion, he did take an active part in events sponsored by the RCIP group, such as a reception held in honor of the visiting Chinese Commissioner of Patents and Trademarks. This Orwellian equality was a little grating, not least because Noam had sold his practice to RCIP before taking up his appointment as Commissioner.

In the small and close knit Israel IP world, most practitioners have come through one of two or three established firms. It is difficult to imagine that anyone with IP experience and knowledge, who hasn’t come through the patent office, won’t have worked for one or other large IP firm. It would be more problematic if someone from Israel industry, say, an in-house IP counsel of Teva, Orbotech or Comverse was appointed commissioner. We do, however, note that the make-up of the committee who considered candidates for the job has not been published. This does not seem a desirable state of affairs for open government.


Counting Sheep for Insomnia – Do sheep count???

March 9, 2011

Neurim’s appeal against the refusal of the UK Patent Office to issue a Supplementary Protection Certificate for Circadin has been referred to the European Court of Justice –the CJEU by the Court of Appeal.

Background

Before a new drug is allowed to be used, regulatory approval is required. This typically takes several years and the drug usually reaches the market towards the end of the 20 years of regular patent protection. It will be appreciated that to bring a drug to market costs hundreds of millions of dollars and very few potential drugs obtain regulatory approval and can be prescribed. There is generally believed to be a market failure in the regular patent regime in that the period over which the patent enables the company that developed a drug to sell at monopolistic prices is considered insufficient to enable the drug developer to recoup their investment and make a reasonable profit.

It is therefore argued that under the standard patent term, there is no incentive to develop and bring new drugs to market. Consequently, various countries that have drug development industries, or which are bullied by countries having drug development industries have adopted patent term extensions, or, as they are called in Europe, Supplementary Protection Certificates (SPCs) which effectively extend the patent for up to an additional 5 years beyond the regular patent protection period of 20 years from filing.

There is, however, a catch. To prevent evergreening – extending patents indefinitely thereby preventing generic competition – such Supplementary Protection Certificates (SPCs) may only be obtained following the first regulatory approval.

The case

Neurim, an Israeli ethical drug company has developed a revolutionary and patented treatment for insomnia based on use of the natural hormone melatonin. The drug, called Circadin, took 15 years to obtain regulatory approval from when their first patent application (European Patent Number EP (UK) No. 0 518 468) was filed on 23 April 1992.

On obtaining regulatory marketing approval in June 2007, Neurim requested an SPC under Art. 3(d) of the SPC Regulation EEC 1768/92 (now EC 469/2009), claiming that this was the “first authorization to place the product on the market as a medicinal product”.

However the British Intellectual Property Office (UK IPO) refused the request on the basis that Circadin was not the first marketing authorization for Melatonin, since another party had obtained approval for “Regulin”, a melatonin medicine for sheep, back in 2001, issued by the UK Veterinary Medicines Directorate under Directive 81/851/EEC. The decision was appealed to and upheld by the court of first instance, and was then appealed to the Court of Appeal who has referred the case to the CJEU.

The Court of Appeal was required to interpret Art 3 of the SPC Regulation and determine whether a valid authorisation had been given for “the product” in question.

The UKIPO argued that melatonin was “the product” and therefore authorisation had been given when it was approved for use in sheep. Neurim argued that sheep were irrelevant – an SPC is just that: protection supplementing the protection of the basic patent. Therefore, as each patent can have its own SPC (but only one), the relevant Marketing Approval for that patent is a marketing approval for a product falling within the scope of that patent.

In the Court of first instance, Justice Arnold was of the opinion that the Regulation was clear, and upheld the IPO’s assessment of the relevancy of the sheep. The Court of Appeal was not so convinced:

Lord Justice Jacob:

“We consider that Neurim’s arguments are not only tenable: in our view they are right. Many kinds of valuable pharmaceutical research will not get the encouragement or reward they deserve if they are not. Pharmaceutical research is not confined to looking for new active compounds. New formulations of old active substances are often sought. Most are unpatentable but from time to time a real invention is made and patented.

Moreover there is much endeavour to find new uses for known active ingredients. The European Patent Convention 2000 has indeed made the patenting of inventions in this area clearer. Its effect is that a patent for a known substance or composition for use in a method of treatment is not to be regarded as old (and hence unpatentable) unless use for that method is known. It would be most unfortunate if second medical use patents could not get the benefit of an SPC.”

For more information, see: the SPC Blog here and here

Court of Appeal: Neurim Pharmaceuticals v The Comptroller-General of Patents [2011] EWCA Civ 228.

COMMENT

Neurim’s Circadin is the only ethical drug other than Teva’s Copaxone that has been developed and brought to market by an Israeli company. The patent in question, and the other patents in Neurim’s portfolio was drafted and prosecuted by my late partner, Dr Stanley Davis.

JMB, Factor & Co. weren’t involved in requesting the SPC in the UK, but have been involved in a corresponding request to the Israel Patent Office. Under current Israel Law (pending an amendment), the extension available in Israel is for the shortest extension granted by a country offering patent term extensions. Consequently, the extension in Israel may be invalid due to the UK case.

Strange things happen when prosecuting pharmaceutical patents. In Korea, a scientific paper relating to Melatonin in cod fish was cited against the corresponding application as rendering treatment by melatonin obvious. One would imagine that fish and humans have very different physiologies. By comparison, sheep and humans are somewhat similar, but Regulin is not a treatment for insomnia in sheep (I believe they count people to induce sleep).

Apparently Regulin improves the reproductive performance of pure bred and crossbred lowland sheep which are to be mated early in the season before the usual peak of reproductive activity. Regulin is recommended for use in Suffolk and Suffolk cross type flocks to cause lambing to start between early December and mid January and in Mule and halfbred flocks to start lambing between late December and mid February.

We await developments with interest.


Thesaurus of Claim Construction – a book review

March 4, 2011

I was very excited when Stuart Soffer, a Non-Resident Fellow, Stanford Law School Center for Internet and Society informed me of his forthcoming book, “Thesaurus of Claim Construction” which is co-authored with Robert C. Kahrl, a long term partner at Jones Day. Such a book is long overdue.

The nice people at Oxford University Press kindly sent me a copy.

The work is mostly an alphabetic arrangement of words and phrases that have been construed in the course of patent litigation and includes over 7000 entries. Since such constructions are, by definition, rulings regarding the meaning of the word or phrase in the specific context. Consequently such constructions are not binding precedents and aren’t even much use as an indication of what a phrase would be interpreted to mean in another claim construction. Nevertheless, the definitions do show what the words could be taken to mean.

The range of words and phrases that have been the subject of claim construction may be surprising to some. Chief Judge Markey in Senmed vs. Richard Allan Medical Industries, Inc 888 F.2d 8215, 819 n. 8 (1989) commented on a construction of the word ‘on’ in a claim, that;

 ”lawyers may create a dispute about any word”.

Chapter 1, ‘How to use this book’ is well worth reading, but I rarely bother with user manuals and certainly have no intention to review a user manual for a book, so will move on.

Chapter 2, titled ‘Outline of the Law of Claim Construction’ is a must read for litigators and is valuable reading for practitioners drafting claims. Personally, I believe that expensive disputes could be avoided by using words more carefully, preferably in accordance with their regular meanings and with definitions in the specification. Nevertheless, it is valuable to review the hierarchy between dictionary definitions, the specification, extraneous sources and the file wrapper. There are also differences in how the preamble, transitional phrases and limiting clauses are interpreted. It is useful to remember that the correct construction is what the word meant at the time of filing, apart from the cases where limitations crept in during prosecution.

The lion’s share of the book is devoted to Chapter 3, an alphabetical list of “Simple terms” that have been construed at some time or other, with indications of which definition and which party prevailed and which constructions were rejected. The entries are referenced with the details of the court dockets for further reference.

The list starts with a construction of the symbol %, and reminds us that compositions should be given as weight percent, or volume percent, and that it should be clear if the percentage is of the total composition, or of only part. The next words to be examined are ‘a’ and ‘the’. One can understand why a term like ‘AC energy’ required construction as it is ambiguous, since current is measured in amps and energy in joules, but who would have the foresight to define whether ‘AC wave’ implies the wave created by a varying current over time, or whether the direction of the current has to keep reversing? Likewise the effect of adding words like ‘about’ in a claimed range becomes clearer on reviewing the way such claims are construed.

It will be appreciated that words beginning with letters B through Z have also been construed and this review is not intended to comment comprehensively on all the entries. One can amuse oneself by opening randomly and seeing what terms have been discussed though. For instance, in a particularly adolescent moment I discovered how the court interpreted the term nipple cover.

 In Allure Home Creations vs. Zak, the term ‘second vessel’ was interpreted to mean ‘a preformed sealed vessel enclosing a first liquid and an insoluble structure floating on the first liquid. One presumes, therefore, that the context had nothing to do with first and second vessels relating to reheating foodstuffs on the Jewish Sabbath without violating the Biblical prohibition of cooking – tha is unless the claimed invention related to chicken soup with kneidlach (matzo balls).

One of my esteemed Israeli competitors has the endearing habit of defining the word plurality to mean ‘one or more’ in his specifications. Native English speakers working for him have been unable to convince him that this is simply wrong. I was pleased, therefore to see that the many constructions of the word plurality all take the word to mean at least two. Nevertheless, one wonders how his claims would be construed.

The book relates to litigation in the US, but, since the US is an important market, and because judges everywhere seem to have little scientific aptitude and lawyers everywhere play semantic games, the book will appeal to an international audience. 

In addition to giving the history of Marksman there is also a valuable chapter on ‘means + function’ claims and how they are construed.  Apart from guiding litigators, the book may help claim drafting, should help designing around, and will prove invaluable to practitioners required to express opinions about the work of others. It is also an impressive addition to one’s shelf of dictionaries and reference books, since it has approximately similar dimensions to standard editions of Roget’s prior art.

Thesaurus of Claim Construction, Robert C Kahrl and Stuart B. Soffer, Oxford University Press 2011. Well worth the $295 asking price.


Follow

Get every new post delivered to your Inbox.

Join 90 other followers